Suggested remit - To appraise the clinical and cost effectiveness of fingolimod within its marketing authorisation for treating relapsing multiple sclerosis in children and young people.
Status Awaiting development
Decision None selected
Process STA pre-2018
ID number 1378

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
31 May 2018 (14:00) Scoping workshop (Manchester)
22 March 2018 - 23 April 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual